OLX72021

Small molecule

OOlix Pharmaceuticals, Inc.

OLX72021 is one of 28 small molecule programs targeting Androgenetic Alopecia. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Androgenetic AlopeciaActive, not recruiting

Androgenetic AlopeciaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

62 competitors in Androgenetic Alopecia

#DrugCompanyPhaseTrials

Rogaine

Pfizer

Approved

11 2

Depakote

Zyrtec

2 4

Avodart

Akero Therapeutics

Phase 3

4 5

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

—6

XEOMIN

MMerz Pharmaceuticals GmbH

Zolymbus

1 8

Platelet Rich Plasma

ZZagazig University

Phase 2

2 9

AS101

BBioMAS Ltd

Phase 2

1 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Androgenetic Alopecia

NCT07327359

Clinical

Trials by Indication[1]

Androgenetic Alopecia1 trial

A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

Recruiting·OOlix Pharmaceuticals, Inc.·Phase 1/2·NCT07327359·158 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OLX72021. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OLX72021 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OLX72021. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Olix Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: OOlix Pharmaceuticals, Inc.

OLX72021

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Androgenetic Alopecia1 trial

References

Drug Info

Quick Facts

Related News